We recently provided the proof-of-concept that a precision nutrition strategy according to an individual’s tissue metabotype, within the context of healthy dietary guidelines, results in a clinically relevant further improvement in insulin sensitivity and cardiometabolic health (C-reactive protein and plasma triacylglycerol concentrations) in individuals with overweight or obesity, independent of body weight change [14]. The gene discussed is INS; the disease is Obesity.